3-羟基-1-萘酸 | 19700-42-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 3-羟基-1-萘酸
• 英文名称: 3-hydroxy-1-naphthalenecarboxylic acid
• 英文别名: 3-hydroxy-2-naphthenoic acid；3-hydroxy-1-naphthoic acid；3-hydroxy-[1]naphthoic acid；3-Oxy-naphthalin-carbonsaeure-(1)；3-Hydroxy-[1]naphthoesaeure；3-hydroxy-1-napthalenecarboxylic acid；3-hydroxynaphthalene-1-carboxylic acid
• CAS: 19700-42-6
• 化学式: C₁₁H₈O₃
• 分子量: 188.183
• InChiKey: OCISOSJGBCQHHN-UHFFFAOYSA-N

物化性质

• 熔点：
  242-243 °C
• 沸点：
  450.6±28.0 °C(Predicted)
• 密度：
  1.399±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P330,P363,P501
• 危险性描述：
  H302,H312,H332
• 储存条件：
  2-8°C，干燥

反应信息

• 作为反应物：
  描述：

  3-羟基-1-萘酸 在 sodium hydroxide 、 sodium hypochlorite 、 sodium iodide 作用下， 以 甲醇 为溶剂， 反应 1.0h， 以79.7%的产率得到4-iodo-3-hydroxy-1-naphthoic acid
  参考文献：
  名称：

  Design, Synthesis, and SAR of Tachykinin Antagonists:  Modulation of Balance in NK₁/NK₂ Receptor Antagonist Activity

  摘要：

  Through optimization of compounds based on the dual NK1/NK2 antagonist ZD6021, it was found that alteration of two key regions could modulate the balance of NK1 and NK2 potency. Substitution of the 2-naphthalene position in analogues of ZD6021 resulted in increased NK1 potency and thus afforded NK1 preferential antagonists. Alterations of the piperidine region could then increase NK2 potency to restore dual NK1/NK2 selectivity. Through these efforts, three novel receptor antagonists from a single chemically related series were identified; two are dual NK1/NK2 antagonists, and the third is an NK1 preferential antagonist. In this paper, the factors affecting the balance of NK1 and NK2 selectivity in this series are discussed and the in vitro and in vivo properties of the novel antagonists are described.

  DOI：

  10.1021/jm020094i
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 生成 3-羟基-1-萘酸
  参考文献：
  名称：

  Leuck; Perkins; Whitmore, Journal of the American Chemical Society, 1929, vol. 51, p. 1835

  摘要：

  DOI：

文献信息

• [EN] 4-SUBSTITUTED PIPERIDINE DERIVATIVES<br/>[FR] DERIVES DE PIPERIDINE SUBSTITUES EN POSITION 4
  申请人：BIOAXONE THERAPEUTIQUE INC

  公开号：WO2005080394A1

  公开（公告）日：2005-09-01

  Substituted piperidine compounds represented by the structure I are provided, wherein each of Rla, R1b, R1c, R1d, Rle, R1f, R1g, R1h, R2, R2A, R3, R4, A, X, a, x, and n is as defined in the specification. Substituted piperidine compounds of structure I may permeate or penetrate across a nerve cell membrane into the interior of a nerve cell, may inhibit intracellular Rho kinase enzyme found in nerve cells in mammals, and may find utility in repair of damaged nerves in the central and peripheral nervous system of such mammals. These compounds may induce the regeneration or growth of neurites in mammalian nerve cells and may thereby induce regeneration of damaged or diseased nerve tissue. These compounds also find additional utility as antagonists of the enzyme Rho kinase in treatment of disease states in which Rho kinase is implicated. Pharmaceutical compositions containing these substituted piperidine compounds may be useful to promote neurite growth and in the treatment of diseases in which Rho kinase inhibition is indicated.

  提供了由结构I表示的取代哌啶化合物，其中Rla、R1b、R1c、R1d、Rle、R1f、R1g、R1h、R2、R2A、R3、R4、A、X、a、x和n中的每一个如规范中定义。结构I的取代哌啶化合物可能渗透或穿过神经细胞膜进入神经细胞内部，可能抑制哺乳动物神经细胞中的细胞内Rho激酶酶，并可能在这些哺乳动物的中枢和外周神经系统中修复受损神经时发挥作用。这些化合物可能诱导哺乳动物神经细胞中神经突起的再生或生长，从而诱导受损或患病神经组织的再生。这些化合物还可作为Rho激酶酶拮抗剂在治疗涉及Rho激酶的疾病状态中发挥额外作用。含有这些取代哌啶化合物的药物组合物可能有助于促进神经突起的生长，并在需要Rho激酶抑制的疾病治疗中发挥作用。
• EPOXY-OXETANE COMPOUND, METHOD FOR SYNTHESIZING SAME, AND USE OF SAID COMPOUND
  申请人：SHIKOKU CHEMICALS CORPORATION

  公开号：US20200270236A1

  公开（公告）日：2020-08-27

  The purpose of the present invention is to provide: a novel curable compound which can be expected to be used as a raw material for photocurable resins and thermosetting resins; a method for synthesizing said compound; a resin composition containing said compound; and a cured product thereof. This compound is an epoxy-oxetane compound represented by a formula, and this compound has a structure in which two epoxycyclohexyl groups (groups in which an oxirane ring and a cyclohexane ring are condensed) are bonded to an oxetane ring via a connector having one ether bond. In formula (I′), R 1 to R 3 may be the same as, or different from, each other, and each denote a hydrogen atom or a methyl group. n is 1 or 2.

  本发明的目的是提供一种新型可固化化合物，可望用作光固化树脂和热固化树脂的原料；一种合成该化合物的方法；含有该化合物的树脂组合物；以及其固化产物。该化合物是一种由公式表示的环氧-氧杂环己烷化合物，该化合物具有两个环氧环己基团（氧环烷环与环己烷环结合）通过一个具有一个醚键的连接器连接到一个氧杂环己烷环的结构。在公式（I′）中，R1至R3可能相同，也可能不同，每个代表一个氢原子或一个甲基基团。n为1或2。
• N-(2-phenyl-4-piperidinybutyl)-5,6,7,8-tetrahydro-1-naphthalenecarboxamides and their use as neurokinin 1 (NK1) and/or neurokinin 2 (NK2) receptor antagonists
  申请人：Astrazeneca AB

  公开号：US06403601B1

  公开（公告）日：2002-06-11

  Compounds of formula (I), wherein R2 is a 5,6,7,8-tetrahydronaphth-1-yl group which may be substituted (the remaining groups defined herein), and pharmaceutical compositions containing the compounds and methods of using the compounds in the treatment of a condition where antagonism of the NK1 and/or NK2 receptors is beneficial.

  式（I）的化合物，其中R2是一个可以被取代的5,6,7,8-四氢萘基团（在此定义的其余基团），以及含有这些化合物的药物组合物和使用这些化合物治疗NK1和/或NK2受体拮抗有益的方法。
• [EN] CEPHALOSPORIN DERIVATIVES AND METHODS OF USE<br/>[FR] DÉRIVÉS DE CÉPHALOSPORINE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：UNIV KANSAS

  公开号：WO2014071283A1

  公开（公告）日：2014-05-08

  This invention provides cephalosporin derivatives for killing or inhibiting the spread of microorganisms such as non-replicating Mycobacterium tuberculosis and in the treatment of infectious disease.

  这项发明提供了头孢菌素衍生物，用于杀灭或抑制微生物的传播，如非复制的结核分枝杆菌，并用于治疗传染病。
• N-substituted naphthalene carboxamides as neurokinin-receptor antagonists
  申请人：Astra Zeneca AB

  公开号：US06365602B1

  公开（公告）日：2002-04-02

  A compound of formula I wherein: R is alkyl; R1 is optionally substituted phenyl 2-oxo-tetrahydro-1(2H)-pyrimidinyl, or 2-oxo-1-piperidinyl; R2 is hydrogen, alkoxy, alkanoyloxy, alkoxycarbonyl, alkanoylamino, acyl, alkyl, carbamoyl, N-alkylcarbamoyl, N,N-dialkylcarbamoyl where the alkyl groups are the same or different, hydroxy, thioacyl, thiocarbamoyl, N-alkylthiocarbamoyl, or N,N-dialkylthiocarbamoyl where the alkyl groups are the same or different. X1 and X2 are independently hydrogen or halo, provided that at least one of X1 or X2 is halo; and R3, R4, R5 and R6 are independently hydrogen, cyano, nitro, trifluoromethoxy, trifluoromethyl, or alkylsulfonyl are antagonists of at least one tachykinin receptor and are useful in the treatment of depression, anxiety, asthma, pain, inflammation, urinary incontinence and other disease conditions. Process for their preparation are described, as are compositions containing them and their use.

  公式I的化合物中：R是烷基；R1是可选择地取代的苯基2-氧代四氢-1(2H)-嘧啶基，或2-氧代-1-哌啶基；R2是氢、烷氧基、烷酰氧基、烷氧羰基、烷酰胺基、酰基、烷基、氨基甲酰基、N-烷基氨基甲酰基、N,N-二烷基氨基甲酰基（其中烷基基团相同或不同）、羟基、硫代酰基、硫代氨基甲酰基、N-烷基硫代氨基甲酰基、或N,N-二烷基硫代氨基甲酰基（其中烷基基团相同或不同）。X1和X2独立地为氢或卤素，但至少X1或X2中的一个为卤素；R3、R4、R5和R6独立地为氢、氰基、硝基、三氟甲氧基、三氟甲基、或烷基磺酰基，它们是至少一种催吐肽受体的拮抗剂，对治疗抑郁症、焦虑症、哮喘、疼痛、炎症、尿失禁和其他疾病情况有用。描述了它们的制备方法，以及含有它们和它们的用途的组合物。